Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Najean, Y.
Right arrow Articles by Drueke, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Najean, Y.
Right arrow Articles by Drueke, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1989) 4: 350-355
© 1989 European Renal Association-European Dialysis and Transplant Association

research-article

Kinetics of Erythropoiesis in Dialysis Patients Receiving Recombinant Erythropoietin Treatment

Y. Najean, A. Moynot, F. Deschryver, B. Zins, C. Naret, Ch. Jacquot and T. Drueke

Service de Médecine Nucléaire, Hôpital S. Louis, Centre E. Rist; Centre d'Hémodialyse de l'AURA Bessin, and Département de Néphrologie and INSERM U 90, Hôpital Necker Paris, France

Correspondence and offprint requests to: Correspondence and offprint requests to: Yves Najean MD, ScD, Department of Nuclear Medicine, Hôpital St Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France

Correspondence and offprint requests to: Correspondence and offprint requests to: Tilman B. Drueke MD, INSERM Unité 90, Hôpital Necker 75743 Paris Cedex 15, France

In eleven patients with uraemia on intermittent haemodialysis treatment, recombinant human erythropoietin (rHuEpo) was used at a dosage schedule of 100 IU/kg bodyweight thrice weekly. Erythrokinetic studies (blood volume, RBC survival and iron kinetics) were performed in nine cases before and after 6 months of treatment. The remaining two patients had only RBC and plasma volume determinations before and after treatment. Although total blood volume remained unchanged, RBC volume was increased in all cases. Red cell loss was not modified, and quantitative improvement of RBC production was noted in all cases. No qualitative defect of erythroid maturation or release was observed in the treated patients. In conclusion, rHuEpo treatment improves the anaemia of haemodialysis patients by normalising circulating RBC volume only through an increase in red cell production.

Keywords: Anaemia; Erythropoietin; Erythrokinetics; Haemodialysis; Uraemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.